We propose silkworm as an animal model for screening the drug molecules, especially antibiotics, because they exhibit a conserved immune response and similar pharmacokinetics (PK) as mammals and importantly no ethical issues are associated. To evaluate the PK parameters and effectiveness of ofloxacin in silkworm. Silkworms with their ideal body weight of 3.8 g were injected with 40 μL of 2 mg/mL ofloxacin. The hemolymph was collected at different time intervals 0 to 300 minutes. The samples were used for estimating the retention of ofloxacin in silkworm hemolymph by high performance liquid chromatography (HPLC), ultra violet visible (UV-VIS) spectrophotometry, liquid chromatography mass spectroscopy (LC-MS), and Fourier transform infrared spectroscopy (FTIR). PK analysis was performed by using the PK solver MS-Excel add-on software. The HPLC method was standardized for the quantification of ofloxacin in silkworm. Further with reference, the structure of ofloxacin was elucidated on the basis of LC-MS spectral data. We reconfirmed the presence and activity of the ofloxacin in silkworm by UV-VIS spectrophotometry and FTIR spectroscopy. The noncompartmental analysis technique was used to quantitatively evaluate and predict the in vivo fate of drug by modeling the concentration time–data with suitable model. The features of the silkworm described suggest that they are a suitable alternative evaluation model for determining the therapeutic effectiveness of candidate drugs. The availability of a large number of silkworms at low cost and no associated ethical issues makes it a better animal model suitable to screen novel antibiotics for their therapeutic effectiveness.
Get full access to this article
View all access options for this article.
References
1.
ChandrakantK, ArunG, SatyajyotiK, et al.Drug discovery from plant sources: An integrated approach. AYU, 2012:33; 10–19.
2.
OrlansFB, BeauchampTL, DresserR, et al.The Human Use of Animals: Case Studies in Ethical Choice. New York: Oxford University Press; 1998.
3.
BaumansV. Use of animals in experimental research: An ethical dilemma. Gene Ther, 2004:11; S64–S66.
4.
KaitoC, SekimizuK. A silkworm model of pathogenic bacterial infection. Drug Discov Ther, 2007:1; 89–93.
5.
MahajanMS, TanMW, RahmeLG, et al.Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa—Caenorhabditis elegans pathogenesis model. Cell, 1999:96; 47–56.
6.
LemaitreB, NicolasE, MichautL, et al.The dorso-ventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 1999:86; 973–983.
7.
BernalA, KimbrellDA, JohnyS, et al.Drosophila Thor participates in host immune defense and connects a translational regulator with innate immunity. Proc Natl Acad Sci U S A, 2000:97; 6019–6024.
8.
JohnyS, LangeLF, SolterLF, et al.New insect system for testing antibiotics. J Parasitol, 2007:93; 1505.
9.
ChampionOL, CooperIAM, JamesSL, et al.Galleria mellonella as an alternative infection model for Yersinia pseudo tuberculosis. Microbiology, 2009:155; 1515–1520.
10.
DussaubatC, BrunetJL, HigesM, et al.Gut pathology and responses to the microsporidium Nosema ceranae in the honey bee Apis mellifera. PLoS One, 2012:7; 37017.
11.
KaitoC, UsuiK, KyumaT, et al.Isolation of mammalian pathogenic bacteria using silkworms. Drug Discov Ther, 2011:5; 66–70.
12.
ReuberTL, PlotnikovaJM, DewdneJY, et al.Correlation of defense gene induction defects with powdery mildew susceptibility in Arabidopsis enhanced disease susceptibility mutants. Plant J, 1998:15; 473.
13.
SekimizuK, HamamotoH. Using silkworms as a laboratory animal to evaluate medicines and foods. Drug Discov Ther, 2016:10; 1–2.
14.
KurokawaK, KaitoC, SekimizuK. Two component signaling in the virulence of Staphylococcus aureus: A silkworm larvae pathogenic agent infection model of virulence. Methods Enzymol, 2007:422; 233–244.
15.
HamamotoH, KurokawaK, KaitoC, et al.Quantitative evaluation of therepeutic effects of antibiotics using silkworms infected with human pathogenic microorganism. Antimicrob Agents Chemother, 2004:48; 3.
16.
InagakiY, MatsumotoY, SekimizuK. Using silkworms to establish alternative animal models for evaluation of drug-induced tissues injury. Drug Discov Ther, 2016:10; 40–43.
17.
HamamotoH, TonoikeA, NarushimaK, et al.Silkworm as a model animal to evaluate drug candidate toxicity and metabolism. Comp Biochem Physiol C Toxicol Pharmacol, 2009:149; 334–339.
18.
HamamotoH, KamuraK, RazanajatovoIM, et al.Effects of molecular mass and hydrophobicity on transport rates through non-specific pathways of the silkworm larva midgut. Int J Antimicrob Agents, 2005:26; 38–42.
19.
SekimizuN, PaudelA, HamamotoH. Animal welfare and use of silkworm as a model animal. Drug Discov Ther, 2012:6; 226–229.
20.
HamamotoH, UraiM, IshiiK, et al.Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat Chem Biol, 2015:11; 127–133.
21.
HossainMS, HamamotoH, MatsumotoY, et al.Use of silkworm larvae to study pathogenic bacterial toxins. J Biochem, 2006:140; 439–444.
22.
UsuiK, NishidaS, SugitaT, et al.Acute oral toxicity test of chemical compounds in silkworms. Drug Discov Ther, 2015:10; 57–61.
23.
HiroshiH, KazuhisaS. Identification of lysocin E using a silkworm model of bacterial infection. Drug Discov Ther, 2016:10; 24–29.
24.
MatsumotoY. Quantitative evaluation of cryptococcal pathogenesis and antifungal drugs using a silkworm infection model with Cryptococcus neoformans. J Appl Microbiol, 2012:112; 138–146.
25.
OriharaY, HamamotoH, KasugaH, et al.A silkworm baculovirus model for assessing the therapeutic effects of antiviral compounds: Characterization and application to the isolation of antivirals from traditional medicines. J Gen Virol, 2008:89; 188–194.
26.
ZimmetP, AlbertiKG, ShawJ. Global and societal implications of the diabetes epidemic. Nature, 2001:414; 782–787.
27.
KaitoC, AkimitsuN, WatanabeH, et al.Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Microb Pathog, 2002:32; 183–190.
28.
NishidaS, OnoY, SekimizuK. Lactic acid bacteria activating innate immunity improve survival in bacterial infection model of silkworm. Drug Discov Ther, 2016:10; 49–56.
29.
YamamotoM, KashimotoT, YoshimuraY, et al.A silkworm infection model to investigate Vibrio vulnificus virulence genes. Mol Med Rep, 2016:14; 4243–4247.
30.
NakamuraI, KanasakiR, YoshikawaK, et al.Discovery of a new antifungal agent ASP2197 using a silkworm model of Aspergillus fumigates infection. J Antibiot, 2017:70; 41–44.
31.
BannoY, ShimadaT, KajiuraZ, et al.The silkworm-an attractive BioResource supplied by Japan. Exp Anim, 2010:59; 139–146.
32.
ZhangY, HuoM, ZhouJ, et al.An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed, 2010:99; 306–314.
33.
FinchRG. The role of new quinolones in the treatment of respiratory tract infections. Drugs, 1995:49; 144–151.
34.
DonDN, HiroshiH, YasuhikoM, et al.Current use of silkworm larvae (Bombyx mori) as an animal model in pharmaco-medical research. Drug Discov Ther, 2015:9; 133–135.
35.
KaltaRR, SharmaR, ChaturvediSC. Simultaneous RPHPLC determination of nitazoxanide and Ofloxacin in combined tablet dosage form. Indian J Pharm Sci, 2008:70; 491–494.
36.
RicardoMB, Gustavo deOF, Armando daSCJ, et al.Determination of ofloxacin in tear by HPLC-ESI-MS/MS method: Comparison of ophthalmic drug release between a new mucoadhesive chitosan films and a conventional eye drop formulation in rabbit model. J Pharma Biomed Analy, 2012:70; 544–548.
37.
SahooS, ChakrabortiC, MishraS, et al.FTIR and XRD investigations of some fluoroquinolones. Int J Pharm Pharmal Sci, 2011:3; 3.
38.
PellegattiM. Preclinical in vivo ADME studies in drug development: A critical review. Expert Opin Drug Metabtoxicol, 2012:8; 161–172.
39.
ChrisAD, JoannaYW. The Cytochrome P450 superfamily complement (CYPome) in the annelid capitellateleta. PLoS One, 2014:9; 11.
40.
KalaiselviL, SriranjaniD, RameshS, et al.Pharmacokinetics of ofloxacin in broiler chicken. J Vet Pharmacol Therap, 2006:29; 185–189.
41.
RupalM, IliasK, PetrosL. Exploring interactions between pathogens and the drosophila gut. Develop Comp Immune, 2016:64; 3–10.
42.
FujiyukiT, ImamuraK, HamamotoH, et al.Evaluation of therapeutic effects and pharmacokinetics of antibacterial chromogenic agents in silkworm model of Staphylococcus aureus infection. Drug Discov Ther, 2010:4; 349–354.
43.
UchidaR, HanaiH, MatsuiH, et al.In vitro and In vivo anti-MRSA activities of nosokomycins. Drug Discov Ther, 2014:8; 249–254.
44.
MatsumotoY, SumiyaE, SugitaT, et al.An invertebrate hyperglycemic model for the identification of anti-diabetic drugs. PLoS One, 2011:6; e16262.
